-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2025-520473-40-00
4
2025-09-29
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-518856-21-00
4
2025-08-28
Mild to severe palmoplantar pustulosis
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2024-519521-37-01
10
2025-07-30
Acute ischemic stroke
-
2024-517568-48-00
5
2025-07-21
Delayed Graft Function after Kidney Transplantation
-
2024-517237-40-00
8
2025-07-03
Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (C
-
2024-516355-41-00
4
2025-06-30
Chronic Inducible urticaria and Chronic Spontaneous Urticaria
-
2024-514539-67-00
4
2025-06-27
Systemic Sclerosis
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-516347-41-00
4
2025-04-29
VEXAS Syndrome
-
2024-516173-76-01
5
2025-04-22
HER2-positive or HER2-low (incl. ultra-low) early breast cancer
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-516380-81-00
4
2025-02-28
Treatment of IgAN
-
2024-511037-35-00
4
2025-01-31
Cyclosporine A is a well known medication and is used to prevent rejec
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2023-510297-14-00
4
2024-12-27
Primary Sclerosing Cholangitis (PSC)
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)